Metastatic prostate cancer (PCa) is not curable due to its ability to acquire therapy resistance. Theoretically, acquired therapy resistance can be driven by changes to previously sensitive cancer cells or their environment and/or by outgrowth of a subpopulation of cancer cells with primary resistance.
Direct demonstration of the latter mechanism in patients with PCa is lacking. Here we present a case report as proof-of-principle that outgrowth of a subpopulation of cancer cells lacking the genomic target and present prior to therapy initiation can drive acquired resistance to targeted therapy and threaten survival in patients with PCa.
NPJ precision oncology. 2024 Dec 02*** epublish ***
Dena P Rhinehart, Jiaying Lai, David E Sanin, Varsha Vakkala, Adrianna Mendes, Christopher Bailey, Emmanuel S Antonarakis, Channing J Paller, Xiaojun Wu, Tamara L Lotan, Rachel Karchin, Laura A Sena
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA., Institute for Computational Medicine at Johns Hopkins University, Baltimore, MD, USA., University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA., Institute for Computational Medicine at Johns Hopkins University, Baltimore, MD, USA. ., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/39623053